Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1067)	3/3/2000 10:23:00 PM
From: scott_jiminez	Read Replies (2) \| Respond to of 4474

I was a bit snappy this afternoon. Apologies to all. Here are the genomics/bioinfo. stocks, 10/11/99 -> 3/3/00 (% change) 1. aria...7100 2. hysq...2080 3. glgc...1877 4. gene...1338 5. incy...1166 6. crgn...1145 7. mygn....751 8. absc....724 9. genxy....522 10. cra.....486 11. vgin....425 12. hgsi...380 13. mlnm..208 14. affx...197 Mike: my point about GLIA and other heavily promoted SI biotech stocks is amply revealed in your post. Gliatech has got to be one of the WORST performing biotech stocks during the last ~8 weeks. In a sector where virtually EVERY STOCK HAS GONE UP 2X, 3X, and more, GLIA has done virtually nothing. Nonetheless, it continues to be advertised as nirvana...and continues to underperform. Meanwhile Ariad, which has been far outpacing its peers since October, DOUBLED SINCE LAST FRIDAY. In short, I strongly disagree with your assessment of GLIA: underperforming stocks tend to behave that way for a reason..and will likely continue to do poorly. The opposite for overachievers. Glia is heavily promoted on SI (along with NRGN, NBIX, BTRN, etc.), Ariad is rarely mentioned beyond this thread. This should strike you right at your 'core'.